A randomised evaluation of low-dose cytarabine arabinoside plus lenalidomide versus single-agent low-dose cytarabine arabinoside in older patients with acute myeloid leukaemia: results from the LI-1 Trial
Coplan, M. Ariti, C. Thomas, I. Upton, L. Sydenham, M. Mehta, P. Islam, S. Kjeldsen, L. Burnett, A. K. Hills, R.
Coplan, M.
Ariti, C.
Thomas, I.
Upton, L.
Sydenham, M.
Mehta, P.
Islam, S.
Kjeldsen, L.
Burnett, A. K.
Hills, R.
Citations
Altmetric:
Abstract
Description
Date
2021
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Coplan M, Ariti C, Thomas I, Upton L, Sydenham M, Mehta P, et al. A Randomised Evaluation of Low-Dose Cytarabine Arabinoside Plus Lenalidomide Versus Single-Agent Low-Dose Cytarabine Arabinoside in Older Patients with Acute Myeloid Leukaemia: Results from the LI-1 Trial. Blood. 2021 Nov;138. PubMed PMID: WOS:000736398804290.